New developments in the urokinase-type plasminogen activator system

Bibliography

• HOWE HL, WINGO PA, THUN MJ etal.: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.J Nat. Cancer Inst. (2001) 93:824–842.
   Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ etal.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl. J. Med. (2001) 344:1031–1037.
   Google Scholar
• COLOMER R, SHAM ON LA, TSAI MS, LUPU R: Herceptin: from the bench to the clinic. Cancer Invest. (2001) 19:49–56.
   PubMed Web of Science ®Google Scholar
• REUNING U, MAGDOLEN V, WILHELM O et al.: Multifunctional potential of the plasminogen activation system in tumour invasion and metastasis. Int. J. Oncol (1998) 13:893–906.
   PubMed Web of Science ®Google Scholar
• RABBANI SA: Metalloproteases and urokinase in angiogenesis and tumour progression. hi Vivo (1998) 12:135–142.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN L: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• ROSENBERG S: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin. Ther. Patents (2000) 10:1843–1852.
   Web of Science ®Google Scholar
• CARMELIET P, COLLEN D: Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. (1998) 91:255–285.
   PubMed Web of Science ®Google Scholar
• ZHOU HM, NICHOLS A, MEDA P, VASSALLI JD: Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO (2000) 19:4817–4826.
   PubMed Web of Science ®Google Scholar
• ••Key in vivo demonstration of the role ofuPAR in invasion and plasminogen activation.
   Google Scholar
• PLOW EG, HERREN T, REDLITZ A, MILES LA, HOOVER-PLOW J: The cell biology of the plasminogen system. FASEB J. (1995) 9:939–945.
   PubMed Web of Science ®Google Scholar
• ELLIS V, BERHRENDT N, DANO K: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell- associated and isolated receptor. J. Biol. Chem. (1991) 266:12752–12758.
   Google Scholar
• LIST K, JENSEN ON, BUGGE TH et al:Plasminogen-independent initiation of the pro-urokinase activation cascade M vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry (2000) 39:508–515.
   Google Scholar
• HANSEN AP, PETROS AM, MEADOWS RP et al.: Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 33:4847–4864.
   PubMed Web of Science ®Google Scholar
• NIENABER VL, DAVIDSON D, EDALJIR et al: Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure Fold. Des. (2000) 8:555–563.
   Google Scholar
• ROLDAN AL, CUBELLIS MV, MASUCCI MT et al.: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. (1990) 9:467–474.
   PubMed Web of Science ®Google Scholar
• ESTREICHER A, WOHLWEND A, BELIN D, SCHLEUNING WD, VASSALLI J: Characterisation of the cellular binding site for the urokinase-type plasminogen activator.' Biol. Chem. (1989) 264:1180–1189.
   Web of Science ®Google Scholar
• PLOUG M, BEHRENDT N, LOBER D, DANO K: Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Sem. Thromb. Hemostasis (1991) 17:183–193.
   PubMed Web of Science ®Google Scholar
• FAZIOLI F, RESNATI M, SIDENIUS Netal.: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. (1997) 16:7279–7286.
   Google Scholar
• BLASI F: The urokinase receptor. A cell surface, regulated chemokine. APMIS (1999) 107:96–101.
   Google Scholar
• APPELLA E, ULLRICH SJ, STOPPELLI MP et al.: The receptor-binding sequence of urokinase: a biological function for the growth-factor module of proteases. Biol. Chem. (1987) 262:4437–4440.
   Web of Science ®Google Scholar
• STRATTON-THOMAS JR, MIN HY, KAUFMAN SE et al.: Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain. Prot. Engin. (1995) 8:463–470.
   PubMedGoogle Scholar
• GOODSON RJ, DOYLE MV, KAUFMAN SE, ROSENBERG S: High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Nati Acad. Sci. USA (1994) 91:7129–7133.
   PubMed Web of Science ®Google Scholar
• PLOUG M: Identification of specific sitesinvolved in ligand binding by photoaffinity labelling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry (1998) 37:16494–16505.
   Google Scholar
• PLOUG M, OSTERGAARD S, HANSEN LB, HOLM A, DANO K: Photoaffinity labelling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry (1998) 37:3612–3622.
   Google Scholar
• GARDSVOLL H, DANO K, PLOUG M: Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis." Biol. Chem. (1999) 274:37995–38003.
   PubMed Web of Science ®Google Scholar
• BDEIR K, KUO A, MAZAR A et al.: A region in domain II of the urokinase receptor required for urokinase binding. J. Biol. Chem. (2000) 275:28532–28538.
   PubMed Web of Science ®Google Scholar
• ENGELHOM LH, BEHRENDT N: Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterisation of the receptor in four primate species. Biol. Chem. (2001) 382:435–442.
   PubMed Web of Science ®Google Scholar
• NAR H, BAUER M, STASSEN JM et al: Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation." Ma Biol. (2000) 297:683–695.
   Google Scholar
• SEIFFERT D, CIAMBRONE G, WAGNER NV, BINDER BR, LOSKUTOFF DJ: The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilisation of active Type 1 plasminogen activator inhibitor. J. Biol. Chem. (1994) 269:2659–2666.
   Google Scholar
• LAWRENCE DA, PALANIAPPAN S, STEFANSSON S et al.: Characterisation of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem. (1997) 272:7676–7680.
   Google Scholar
• WET Y, WALTZ DA, RAO N et al.: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. (1994) 269:32380–32388.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of a non-uPA ligandfor uPAR.
   Google Scholar
• DENG G, CURRIDEN SA, WANG S, ROSENBERG S, LOSKUTOFF D: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. (1996) 134:1563–1571.
   PubMed Web of Science ®Google Scholar
• DENG G, ROYLE G, WANG S, CRAIN K, LOSKUTOFF D: Structural and function analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. Biol. Chem. (1996) 271:12716–12723.
   Web of Science ®Google Scholar
• KANSE SM, KOST C, WILHELM OG, ANDREASEN PA, PREISSNER KT: The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. (1996) 224:344–353.
   PubMed Web of Science ®Google Scholar
• KJOLLER L, HALL A: Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. (2001) 152:1145–1157.
   PubMed Web of Science ®Google Scholar
• ••Elegant study on the cytoskeleton changesassociated with uPAR:vitronectin interactions.
   Google Scholar
• STEFANSSON S, LAWRENCE DA: The serpin PAT-1 inhibits cell migration by blocking integrin alpha-V-beta-3 binding to vitronectin. Nature (1996) 383:441–443.
   PubMed Web of Science ®Google Scholar
• CZEKAY RP, KUEMMEL TA, ORLANDO RA, FARQUHAR MG: Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mo/. Biol. Cell (2001) 12:1467–1479.
   PubMed Web of Science ®Google Scholar
• SAKTHIVEL R, ZHANG JC, STRICKLAND DK, GAFVELS M, MCCRAE KR: Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation. I Biol. Chem. (2001) 276:555–562.
   Google Scholar
• NYKJAER A, CONESE M, CHRISTENSEN El et al.: Recycling of the urokinase receptor upon internalisation of the uPA:serpin complexes. EMBO J. (1997) 16:2610–2620.
   PubMed Web of Science ®Google Scholar
• ••Key reference defining the uPA:uPARclearance cycle.
   Google Scholar
• CHAPMAN HA: Plasminogen activators, integrins, and the co-ordinated regulation of cell adhesion and migration. Curt: Opin. Cell Biol. (1997) 9:714–724.
   PubMed Web of Science ®Google Scholar
• BOHUSLAV J, HOREJSI V, HANSMANN C et al: Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. Exp. Med. (1995) 181:1381–1390.
   PubMed Web of Science ®Google Scholar
• SIMON DI, RAO NK, XU H et al: Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood (1996) 88:3185–3194.
   PubMed Web of Science ®Google Scholar
• WET Y, LUKASHEV M, SIMON DI et al.: Regulation of integrin function by the urokinase receptor. Science (1996) 273:1551–1555.
   PubMed Web of Science ®Google Scholar
• ••First direct evidence defining thefunctional effects of uPAR:integrin interactions.
   Google Scholar
• CHAPMAN HA, WET Y, SIMON DI, WALTZ D: Role of urokinase receptor and caveolin in regulation of integrin signalling. Thromb. Haemostasis (1999) 82:291–297.
   PubMed Web of Science ®Google Scholar
• SIMON DI, WET Y, ZHANG L et al.: Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function.' Biol. Chem. (2000) 275:10228–10234.
   Google Scholar
• XUE W, MIZUKAMI I, TODD RF 3, PETTY HR: Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. (1997) 57:1682–1689.
   PubMed Web of Science ®Google Scholar
• GHOSH S, BROWN R, JONES JC, ELLERBROEK SM, STACK MS: Urinary-type plasminogen activator (uPA) expression and uPA receptor localisation are regulated by alpha 3 beta 1 integrin in oral keratinocytes. J. Biol. Chem. (2000) 275:23869–23876.
   PubMed Web of Science ®Google Scholar
• CARRIERO MV, DEL VECCHIO S, CAPOZZOLI M et al.: Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. (1999) 59:5307–5314.
   PubMedGoogle Scholar
• YEBRA M, PARRY GC, STROMBLAD S et al.: Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. (1996) 271:29393–29399.
   PubMed Web of Science ®Google Scholar
• CHAPMAN HA, WET Y: Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemostasis (2001) 86:124–129.
   PubMed Web of Science ®Google Scholar
• ••Most up to date review on uPAR:integrincross-talk.
   Google Scholar
• SITRIN RG, PAN PM, BLACKWOOD RA, HUANG J, PETTY HR: Cutting edge: evidence for a signalling partnership between urokinase receptors (cd87) and L-selectin (cd621) in human polymorphonuclear neutrophils. Immunol (2001) 166:4822–4825.
   Web of Science ®Google Scholar
• ZHANG JC, CLAFFEY K, SAKTHIVELR et al.: Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB (2000) 14:2589–2600.
   PubMed Web of Science ®Google Scholar
• CHAVAKIS T, KANSE SM, LUPU F et al: Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood (2000) 96:514–522.
   PubMed Web of Science ®Google Scholar
• COLMAN RW, PIXLEY RA, NAJAMUNNISA S et al.: Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. Clin. Invest. (1997) 100:1481–1487.
   Google Scholar
• GODAR S, HOREJSI V, WEIDLE UH et al.: M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-betal . Eur. Immunol (1999) 29:1004–1013.
   PubMed Web of Science ®Google Scholar
• NYKJAER A, CHRISTENSEN El, VORUM H et al.: Mannose 6-phosphate/ insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell. Biol. (1998) 141:815–828.
   PubMed Web of Science ®Google Scholar
• BEHRENDT N, JENSEN ON, ENGELHOLM LH et al: A urokinase receptor-associated protein with specific collagen binding properties. J. Biol. Chem. (2000) 275:1993–2002.
   PubMed Web of Science ®Google Scholar
• ALBO D, ROTHMAN VL, ROBERTS DD, TUSZYNSKI GP: Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br. J. Cancer (2000) 83:298–306.
   PubMed Web of Science ®Google Scholar
• AGUIRRE-GHISO JA, KOVALSKI K, OSSOWSKI L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signalling.' Cell. Biol. (1999) 147:89–104.
   PubMed Web of Science ®Google Scholar
• AGUIRRE-GHISO JA, LIU D, MIGNATTI A, KOVALSKI K, OSSOWSKI L: Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy M vivo. Mol. Biol. Cell(2001) 12:863–879.
   PubMed Web of Science ®Google Scholar
• WALTZ DA, FUJITA RM, YANG X et al.: Nonproteolytic role for the urokinase receptor in cellular migration M viva Am. J. Resp. Cell. Mol. Biol. (2000) 22:316–322.
   PubMed Web of Science ®Google Scholar
• MAY AE, KANSE SM, LUND LR et al.: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. (1998) 188:1029–1037.
   PubMed Web of Science ®Google Scholar
• FOEKENS JA, PETERS HA, LOOK MP et al.: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. (2000) 60:636–643.
   PubMed Web of Science ®Google Scholar
• ••An ongoing extensive analysis of theprognostic value of the uPA system in breast cancer.
   Google Scholar
• ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. Cancer (1997) 72:1–22.
   PubMed Web of Science ®Google Scholar
• ••Excellent and comprehensive review of theuPA system in cancer.
   Google Scholar
• JANICKE F, PRECHTL A, THOMSSEN C et al.: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor Type 1. J. Nati Cancer Inst. (2001) 93:913–920.
   PubMed Web of Science ®Google Scholar
• ••First clinical demonstration of the utility ofuPA system component levels in prognosis and treatment of breast cancer.
   Google Scholar
• BUGGE TH, KOMBRINCK KW, XIAO Q et al.: Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood (1997) 90:4522–4531.
   PubMed Web of Science ®Google Scholar
• BUGGE TH, LUND LR, KOMBRINCK KK et al.: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 16:3097–3104.
   PubMed Web of Science ®Google Scholar
• SHAPIRO RL, DUQUETTE JG, ROSES DF et al.: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. (1996) 56:3597–3604.
   PubMed Web of Science ®Google Scholar
• TRESSLER RJ, PITOT PA, STRATTON JR et al.: Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS (1999) 107:168–173.
   PubMed Web of Science ®Google Scholar
• FRANDSEN TL, HOLST-HANSEN C, NIELSEN BS et al.: Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res. (2001) 61:532–537.
   PubMed Web of Science ®Google Scholar
• ••Role of non-tumour cell derived uPA intumour progression.
   Google Scholar
• BAJOU K, NOEL A, GERARD RD et al.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. (1998) 4:923–928.
   PubMed Web of Science ®Google Scholar
• ••Elegant analysis of the functional role ofPAT-1 in angiogenesis by gene transfer.
   Google Scholar
• BAJOU K, MASSON V, GERARD RD et al.: The plasminogen activator inhibitor PAI-1 controls M vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.' Cell. Biol. (2001) 152:777–784.
   Google Scholar
• GUTIERREZ LS, SCHULMAN A, BRITO-ROBINSON T et al.: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. (2000) 60:5839–5847.
   PubMed Web of Science ®Google Scholar
• MCMAHON GA, PETITCLERC E, STEFANSSON S et al.: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. Biol. Chem. (2001) 276:33964–33968.
   Web of Science ®Google Scholar
• STEFANSSON S, PETITCLERC E, WONG MK et al.: Inhibition of angiogenesis M vivo by plasminogen activator inhibitor-1. J. Biol. Chem. (2001) 276:8135–8141.
   PubMed Web of Science ®Google Scholar
• MIN HY, DOYLE LV, VITT CR et al.: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. (1996) 56:2428–2433.
   PubMed Web of Science ®Google Scholar
• ••First direct demonstration of a role for theuPA system in tumour angiogenesis.
   Google Scholar
• LI H, GRISCELLI F, LINDENMEYER F et al.: Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Human Gene Then (1999) 10:3045–3053.
   PubMed Web of Science ®Google Scholar
• DEL ROSSO M, FIBBI G, MATUCCI-CERINIC M: The urokinase-type plasminogen activator system and inflammatory joint diseases. Gin. Exp. Rheumatol. (1999) 17:485–498.
   PubMed Web of Science ®Google Scholar
• YANG YH, CARMELIET P, HAMILTON JA: Tissue-type plasminogen activator deficiency exacerbates arthritis. Immunol. (2001) 167:1047–1052.
   Web of Science ®Google Scholar
• SIDENIUS N, SIER CF, ULLUM H et al.: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 96:4091–4095.
   PubMed Web of Science ®Google Scholar
• WADA M, WADA NA, SHIRONO H et al.: Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem. Biophys. Res. Commun. (2001) 284:346–351.
   PubMed Web of Science ®Google Scholar
• WILSON KJ, ILLIG CR, SUBASINGHE N et al.: Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:915–918.
   PubMed Web of Science ®Google Scholar
• KLINGHOFER V, STEWART K, MCGONIGAL T et al.: Species specificity of amidine-based urokinase inhibitors. Biochemistry (2001) 40:9125–9131.
   PubMed Web of Science ®Google Scholar
• KRUGER A, SOELTL R, LUTZ V et al.: Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Then (2000) 7:292–299.
   PubMed Web of Science ®Google Scholar
• VAN DER LAAN WH, PAP T, RONDAY HK et al.: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritic Rheum. (2000) 43:1710–1718.
   Google Scholar
• QUAX PH, LAMFERS ML, LARDENOYE JH et al.: Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation (2001) 103:562–569.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, SUGINO D, SHE MY et al.: A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Ear: Biochem. (1998) 253:817–826.
   PubMedGoogle Scholar
• YU W, KIM J OSSOWSKI L: Reduction insurface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell. Biol. (1997) 137:767–777.
   PubMed Web of Science ®Google Scholar
• DEL ROSSO M, FIBBI G, PUCCI M, CERINIC MM: Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. Clin. Exp. Rheumatol. (1998) 16:389–393.
   PubMed Web of Science ®Google Scholar
• NGO TH, HOYLAERTS ME KNOCKAERT I, BROUWERS E, DECLERCK PJ: Identification of a target-site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric upregulation of its anti-adhesive properties. J Biol. Chem. (2001) 276:26243–26248.
   PubMed Web of Science ®Google Scholar
• CHAPPUIS PO, DIETERICH B, SCIRETTA V et al: Functional evaluation of plasmin formation in primary breast cancer. J. Clin. Oncol. (2001) 19:2731–2738.
   PubMed Web of Science ®Google Scholar
• PEDERSEN AN, CHRISTENSEN IJ, STEPHENS RW et al.: The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res. (2000) 60:6927–6934.
   PubMed Web of Science ®Google Scholar
• WEBB DJ, THOMAS KS, GONIAS SL: Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signalling and thereby promotes MCF-7 cell growth. J. Cell. Biol. (2001) 152:741–752.
   PubMed Web of Science ®Google Scholar
• DEGRYSE B, RESNATI M, RABBANI SA et al.: Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood (1999) 94:649–662.
   PubMed Web of Science ®Google Scholar
• RESNATI M, GUTTINGER M, VALCAMONICA S et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO. (1996) 15:1572–1582.
   PubMed Web of Science ®Google Scholar
• WEBB DJ, NGUYEN DH, GONIAS SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. Cell Sci. (2000) 113:123–134.
   PubMed Web of Science ®Google Scholar
• KOSHELNICK Y, EHART M, HUFNAGL P, HEINRICH PC, BINDER BR: Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. j Biol. Chem. (1997) 272:28563–28567.
   PubMed Web of Science ®Google Scholar
• FIBBI G, CALDINI R, CHEVANNE M etal.: Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab. Invest. (1998) 78:1109–1119.
   Google Scholar
• KUSCH A, TKACHUK S, HALLER H et al: Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. .1 Biol. Chem. (2000) 275:39466–39473.
   PubMed Web of Science ®Google Scholar